Amgen

Open: 261.7 Close: 262.51 Change: 0.81

The unbelievably easy way to evaluate Amgen: Use an AI.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, close, last, acquisition, share, announce, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%. Amgen plans to close its $28 billion Horizon Therapeutics acquisition in December this year.

Today's News

The main benchmarks closed higher ahead of this weeks key inflation update. Boosting the 30-stock index was Amgen (+4.0%), which continued to climb following last weeks better-than-expected second-quarter earnings report. Amgen Inc. is graded B on this front, indicating that it is trading at a discount to its peers. The facts discussed here and much other information on Zacks.com might help determine whether or not its worthwhile paying attention. Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%. Amgen plans to close its $28 billion Horizon Therapeutics acquisition in December this year. This acquisition will give Amgen ammunition to combat the competition for Enbrel. The Internal Revenue Service (IRS) was seeking more than $5 billion in back taxes, plus interest and penalties related to Amgens accounting for profits between the U.S. and China. On this news, shares of Amgen fell more than 6%. Iain D. Campuzano PhD FRSC FRSC Scientific Associate Director at Amgen. Patient Support Program Operations Supervisor is an organization with a powerful sense of purpose toward our mission: to serve patients. At Amgen, our shared mission-to serve patients-drives all that we do. Amgen stock last closed at $262.51 , up 0.17% from the previous day, and has increased 5.7% in one year. Amgen is currently +24% from its 52-week low of $211.71, and -11.51% from $296.67. 8 Wall Street analysts who monitor Amgen, their consensus recommendation is to buy Amgen stock. Perpetual Ltd, a prominent investment firm, has announced its acquisition of a new stake in shares of Amgen Inc. Hedge funds and institutional investors collectively own 74.70% of Amgen stock. With a market capitalization amounting to $135.15 billion, Amgen presents itself as an attractive investment opportunity. Amgen recently announced a quarterly dividend scheduled for payment on September 8th. Amgen is an Equal Opportunity Employer and will consider all qualified applicants for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, protected veteran status or disability status. Amgen (NASDAQ:AMGN – Get Free Report ) last posted its quarterly earnings results on Thursday, August 3rd. Amgen had a net margin of 30.02% and a return on equity of 226.41%. Amgen also recently announced a quarterly dividend, which will be paid on September 8th.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

How much time have you spent trying to decide whether investing in Amgen? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, stock, close, last, acquisition, share, announce, and the most common words in the summary are: amgen, stock, job, market, news, inc, best, . One of the sentences in the summary was: Amgen stock (NASDAQ: AMGN) has seen a 17% rise in a month, outperforming the broader S&P500 index, up 1%. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #stock #job #market #news #inc #best.